Mansukhlal Ramolia, MD
Family Medicine · Chesapeake, VANPI 1679502413
Payments from drug & device makers
Across 352 payments — averaging $16.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$689
- Boehringer Ingelheim$646
- Pfizer$478
- AbbVie$477
- GSK$471
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,775100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 56 | $1,005 |
| Novo Nordisk | 44 | $689 |
| Boehringer Ingelheim | 43 | $646 |
| Pfizer | 31 | $478 |
| AbbVie | 29 | $477 |
| GSK | 32 | $471 |
| Amarin Pharma, Inc. | 15 | $214 |
| Medicure Pharma Inc. | 1 | $202 |
| Merck | 12 | $178 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $161 |
| Amgen | 10 | $140 |
| Esperion Therapeutics, Inc. | 8 | $120 |
| Lilly USA, LLC | 8 | $104 |
| Sanofi-aventis U.S. LLC | 5 | $98 |
| Boston Scientific | 4 | $81 |
| Astellas Pharma US Inc | 4 | $74 |
| Johnson & Johnson | 4 | $64 |
| Dexcom, Inc. | 4 | $63 |
| E.r. Squibb & Sons, L.L.C. | 4 | $59 |
| Novartis | 3 | $57 |
| Sanofi Pasteur Inc. | 3 | $49 |
| Daiichi Sankyo Inc. | 2 | $47 |
| Kowa Pharmaceuticals America, Inc. | 3 | $38 |
| Abbott | 2 | $37 |
| Hikma Pharmaceuticals USA | 2 | $31 |
| Corcept Therapeutics | 1 | $25 |
| Nevro Corp. | 1 | $22 |
| Bayer | 1 | $21 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Harmony Biosciences LLC | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Verona Pharma, Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| Circassia Inc. | 1 | $14 |
| Almatica Pharma LLC | 1 | $13 |
| Cequr Corporation | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,781 in reported general payments places this provider in the 85th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 54 | $69,065 |
| FarxigaDapagliflozin Propanediol | 67 | $54,953 |
| JanumetSitagliptin Phos/Metformin Hcl | 40 | $40,549 |
| XareltoRivaroxaban | 27 | $31,896 |
| OzempicSemaglutide | 26 | $28,878 |
| EliquisApixaban | 25 | $25,355 |
| TrulicityDulaglutide | 25 | $25,316 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $22,804 |
| JanuviaSitagliptin Phosphate | 31 | $22,071 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 21 | $16,980 |
| LinzessLinaclotide | 12 | $10,405 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 23 | $9,442 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $7,083 |
| Rosuvastatin Calcium | 276 | $3,574 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $3,551 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet, Januvia, Janumet Xr | $178 | $79,60192 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $646 | $78,50777 claims |
| AstraZenecaFarxiga | $1,005 | $54,95367 claims |
| Johnson & JohnsonXarelto | $64 | $31,89627 claims |
| Novo NordiskOzempic | $689 | $28,87826 claims |
| PfizerEliquis | $478 | $25,35525 claims |
| Lilly USA, LLCTrulicity | $104 | $25,31625 claims |
| GSKTrelegy Ellipta | $471 | $22,80429 claims |
| AbbVieLinzess | $477 | $10,40512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Chesapeake
- Samir AbdelshaheedChesapeake$642K
- Aaron HartmanMidlothian$17.4M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
- Linda SchneiderHampton$2.1M
- Jennifer BrownMidlothian$1.3M
- Brian McCormickHampton$793K
- Jerome DanielNorth Chesterfield$779K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.